Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Halo-substituted piperidines as orexin receptor modulators

A halogen and substituent technology, applied in anti-inflammatory agents, metabolic diseases, non-central analgesics, etc.

Active Publication Date: 2019-01-15
ASTRAZENECA AB +1
View PDF17 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, many reported orexin receptor modulators, such as antagonist ligands, have suboptimal metabolic stability

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Halo-substituted piperidines as orexin receptor modulators
  • Halo-substituted piperidines as orexin receptor modulators
  • Halo-substituted piperidines as orexin receptor modulators

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0423] Embodiment 1: synthetic scheme

[0424] Exemplary chemical entities useful in the methods of the present application will now be described by reference to the illustrative synthetic schemes for the general preparations below and the specific examples that follow. The skilled artisan will recognize that in order to obtain the various compounds of the present application, the starting materials can be appropriately selected such that the final desired substituents are carried through the reaction schemes, with or without protection, as appropriate, to produce the desired desired product. Alternatively, it may be necessary or desirable to use an appropriate group in place of the final desired substituent, which group can be worked through the reaction scheme and replaced with the desired substituent as appropriate. Furthermore, those skilled in the art will recognize that the permutations shown in the schemes below can be performed in any order compatible with the funct...

Embodiment 2

[1214] Example 2: Functional Assay Based on Orexin Receptor Cells

[1215] Measured using FLIPR [Ca 2+ ]i: In F12-K medium supplemented with 10% FBS, CHO-OX 1 or CHO-OX 2 Cells were seeded into black-walled transparent-bottom 384-well plates (Corning, catalog number 3712) at a density of 20,000 cells / well, and then incubated 2 , Incubate overnight in a 37°C incubator to reach 90% confluence. Cells were incubated with an equal volume of Calcium 6 loading buffer (Molecular Devices, Inc.) containing 2.5 mM probenecid for 2 hours at 37°C and then re-incubated with test compounds (dose range 0.1 nM-10 μM). Incubate for 30 minutes. The plate was then placed in FLIPR (Molecular Devices, Inc.) to react with [OX]-added EC 90 Fluorescence was monitored before and after (λ excitation 488 nm, lambda emission 540 nm). Results for Exemplary Compounds of Formula (I), (Ia), (Ib), (II), (IIa), (III), (IIIa), (IV), (IVa), (V) or (Va) Shown in Table 3.

[1216] Table 3: Exemplary compoun...

Embodiment 3

[1223] Example 3: Nicotine Self-Administration Assay

[1224] For all experiments, rats weighing 250-300 g were housed in groups of 1-23 / cage in a temperature-controlled vivarium on a reversed 12-h light / dark cycle (lights off at 8 a.m. ) feeding. Food and water were provided ad libitum until initiation of behavioral training. During training, rats were food-restricted to maintain approximately 85-90% of their body weight on free-feeding. Behavioral testing was performed during the dark portion of the light / dark cycle between 9 am and 1 pm during the early phase of the dark phase of the cycle. All operations were performed in strict compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of The Scripps Research Institute. Rats were anesthetized by inhalation of 1-3% isoflurane / oxygen, and a silicone rubber catheter was inserted into the jugular vein. Briefly, t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

Description

[0001] related application [0002] This application claims priority to U.S. Provisional Patent Application No. 62 / 294,940, filed February 12, 2016, and U.S. Provisional Patent Application No. 62 / 336,102, filed May 13, 2016, which are incorporated by reference in their entirety into this application. [0003] statement of government support [0004] This invention was made with Government support under Grant Numbers 1 P01DA033622 and 1 U01 NS083614 awarded by the National Institutes of Health. The US Government has certain rights in this invention. Background technique [0005] Orexin is a class of homologous peptides, including orexin A or OR-A and orexin B or OR-B. Orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell (1998), 92, 573-585). Orexin is produced in neurons in the lateral hypothalamus and is associated with at least two different species called OX 1 and OX 2 Receptor G protein-coupled receptor binding. OX ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D403/14C07D401/14C07D405/14C07D409/14C07D413/14C07D417/14A61K31/445A61K31/497A61K31/506A61K31/53A61P1/04A61P1/12A61P3/04A61P9/12A61P13/12A61P15/00A61P25/06A61P25/08A61P25/16A61P25/18A61P25/20A61P25/24A61P25/28A61P25/32A61P25/36A61P29/00A61P35/00A61P37/00
CPCA61K31/445A61K31/497A61K31/506A61K31/53A61P1/04A61P1/12A61P3/04A61P9/12A61P13/12A61P15/00A61P25/06A61P25/08A61P25/16A61P25/18A61P25/20A61P25/24A61P25/28A61P25/32A61P25/36A61P29/00A61P35/00A61P37/00C07D401/14C07D403/14C07D405/14C07D409/14C07D413/14C07D417/14A61P25/34
Inventor T·M·卡门内卡J·霍伦茨S·韦斯洛夫斯基何元君R·伯利
Owner ASTRAZENECA AB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com